Interleukin 6 Is Associated with Cachexia in Patients with Prostate Cancer

Urology

Volumn 69, Issue 1, 2007, Pages 113-117

  Kuroda, Kenji ^a   Nakashima, Jun ^a   Kanao, Kent ^a   Kikuchi, Eiji ^a   Miyajima, Akira ^a   Horiguchi, Yutaka ^a   Nakagawa, Ken ^a   Oya, Mototsugu ^a   Ohigashi, Takashi ^a   Murai, Masaru ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL; INTERLEUKIN 6; PROTEIN;

ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY MASS; CACHEXIA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION;

CACHEXIA; HUMANS; INTERLEUKIN-6; MALE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 33846519859     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.09.039     Document Type: Article

References (24)

1. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52 (2002) 72-91
2. Nordan R.P., Pumphrey J.G., and Rudikoff S. Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1. J Immunol 139 (1987) 813-817
3. Hirano T., Yasukawa K., Harada H., et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324 (1986) 73-76
4. Schreiber G., Tsykin A., Aldred A.R., et al. The acute phase response in the rodent. Ann N Y Acad Sci 557 (1989) 61-85
5. Twillie D.A., Eisenberger M.A., Carducci M.A., et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45 (1995) 542-549
6. Giri D., Ozen M., and Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159 (2001) 2159-2165
7. Adler H.L., McCurdy M.A., Kattan M.W., et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161 (1999) 182-187
8. Jewett H.J. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 2 (1975) 105-124
9. Pfitzenmaier J., Vessella R., Higano C.S., et al. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97 (2003) 1211-1216
10. Drachenberg D.E., Elgamal A.A., Rowbotham R., et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41 (1999) 127-133
11. Kuroda K., Horiguchi Y., Nakashima J., et al. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer. Clin Cancer Res 11 (2005) 5590-5594
12. Oka M., Yamamoto K., Takahashi M., et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56 (1996) 2776-2780
13. Tisdale M.J. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 6 (2001) D164-D174
14. Ettinger Jr. W.H., Sun W.H., Binkley N., et al. Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys. J Gerontol [A] Biol Sci Med Sci [A] Biol Sci 50 (1995) M137-M140
15. Strassmann G., and Kambayashi T. Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. Cytokines Mol Ther 1 (1995) 107-113
16. Leng S., Chaves P., Koenig K., et al. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc 50 (2002) 1268-1271
17. Alexandrakis M.G., Passam F.H., Ganotakis E.S., et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 25 (2003) 41-46
18. Ferrucci L., Penninx B.W., Volpato S., et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc 50 (2002) 1947-1954
19. Cohen H.J., Pieper C.F., Harris T., et al. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol [A] Biol Sci Med Sci [A] Biol Sci 52 (1997) M201-M208
20. Wallenius V., Wallenius K., Ahren B., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8 (2002) 75-79
21. Zaki M.H., Nemeth J.A., and Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111 (2004) 592-595
22. Salgado R., Junius S., Benoy I., et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103 (2003) 642-646
23. George D.J., Halabi S., Shepard T.F., et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from Cancer and Leukemia Group B 9480. Clin Cancer Res 11 (2005) 1815-1820
24. Nakashima J., Tachibana M., Horiguchi Y., et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 (2000) 2702-2706